The legal scrutiny follows two distinct market dips tied to clinical trial updates. On September 29, 2025, the company reported positive data for its long-term study of daily subcutaneous injections of nomlabofusp, yet simultaneously disclosed that seven participants had suffered anaphylaxis or severe allergic reactions. The revelation sent Larimar shares tumbling 33.66%, wiping $1.72 off the stock price to close at $3.38.
Nearly a year later, on June 29, 2026, the company confirmed the submission of its rolling Biologics License Application for the drug. Despite the regulatory progress, the announcement included data indicating that anaphylaxis had been reported in 10 of 43 patients. Investors responded by pushing the stock down another 12.57% to close at $3.20. Pomerantz LLP is now examining whether these disclosures reflect broader corporate misconduct or breaches of fiduciary duty, inviting affected shareholders to contact firm representative Danielle Peyton.
Comments (0)
No comments yet. Be the first!